These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35168456)

  • 1. Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.
    Garufi C; Maclean M; Gadina M; Spinelli FR
    Expert Rev Clin Immunol; 2022 Mar; 18(3):309-319. PubMed ID: 35168456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
    Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.
    Rocha CM; Alves AM; Bettanin BF; Majolo F; Gehringer M; Laufer S; Goettert MI
    Inflammopharmacology; 2021 Jun; 29(3):595-615. PubMed ID: 34046798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK inhibitors for rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Opin Investig Drugs; 2023 Apr; 32(4):333-344. PubMed ID: 37014106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
    Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
    Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
    Hammitzsch A; Lorenz G; Moog P
    Front Immunol; 2020; 11():591176. PubMed ID: 33193430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase inhibitors for rheumatoid arthritis.
    Yamaoka K
    Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
    Jegatheeswaran J; Turk M; Pope JE
    Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upadacitinib for the treatment of rheumatoid arthritis.
    Serhal L; Edwards CJ
    Expert Rev Clin Immunol; 2019 Jan; 15(1):13-25. PubMed ID: 30394138
    [No Abstract]   [Full Text] [Related]  

  • 11. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
    Tanaka Y; Kavanaugh A; Wicklund J; McInnes IB
    Mod Rheumatol; 2022 Jan; 32(1):1-11. PubMed ID: 33740386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an
    Frede N; Lorenzetti R; Hüppe JM; Janowska I; Troilo A; Schleyer MT; Venhoff AC; Voll RE; Thiel J; Venhoff N; Rizzi M
    Front Immunol; 2023; 14():1087986. PubMed ID: 36776828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective JAK inhibitors in development for rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
    Harigai M; Honda S
    Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [JAK inhibition in the treatment of inflammatory rheumatic diseases].
    Šenolt L
    Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
    Keeling S; Maksymowych WP
    Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
    El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
    Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
    Qiu Q; Feng Q; Tan X; Guo M
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):547-554. PubMed ID: 31059310
    [No Abstract]   [Full Text] [Related]  

  • 19. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
    Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
    J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.